Publications by authors named "Paul G Richardson"

100Publications

Proteasome inhibition for the treatment of glioblastoma.

Expert Opin Investig Drugs 2020 Aug 10:1-9. Epub 2020 Aug 10.

Department of Neurology, Brain Tumor Center and Comprehensive Cancer Center Zurich, University Hospital and University of Zurich , Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2020.1803827DOI Listing
August 2020

The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?

Br J Haematol 2020 Jun 5. Epub 2020 Jun 5.

Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16764DOI Listing
June 2020

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.

Eur J Haematol 2020 Apr 29. Epub 2020 Apr 29.

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13435DOI Listing
April 2020

Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.

Clin Lymphoma Myeloma Leuk 2020 Jun 7;20(6):351-357. Epub 2020 Mar 7.

Division of Hematology and Oncology, Department of Medicine, Columbia University, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.12.026DOI Listing
June 2020

Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.

Biol Blood Marrow Transplant 2020 Jul 19;26(7):1342-1349. Epub 2020 Mar 19.

Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.03.011DOI Listing
July 2020

Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation.

Br J Haematol 2020 Mar 10. Epub 2020 Mar 10.

Division of Pediatric Oncology, Department of Pediatrics, Perelman School of Medicine, The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16552DOI Listing
March 2020

Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment.

Blood Cancer J 2020 03 4;10(3):29. Epub 2020 Mar 4.

Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0286-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055222PMC
March 2020

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

Cells 2020 Feb 6;9(2). Epub 2020 Feb 6.

Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9020378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072398PMC
February 2020

Selinexor for the treatment of multiple myeloma.

Expert Opin Pharmacother 2020 Mar 19;21(4):399-408. Epub 2020 Jan 19.

Karyopharm Therapeutics, Newton, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1707184DOI Listing
March 2020

Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile.

Br J Haematol 2020 02 30;188(4):483-485. Epub 2019 Sep 30.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16214DOI Listing
February 2020

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

N Engl J Med 2019 08;381(8):727-738

From the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (A.C., S.P., S.J.), and New York University Langone Medical Center (D.K.) - both in New York; the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.T.V.); the School of Medicine, National and Kapodistrian University of Athens, Athens (M.G., M. Dimopoulos); the Winship Cancer Institute, Emory University, Atlanta (A.K.N., S.L.); Massachusetts General Hospital Cancer Center (A.J.Y.), Tufts Medical Center (R.L.C.), and the Dana-Farber Cancer Institute (P.G.R.), Boston, and Karyopharm Therapeutics, Newton (M.G.K., S.S., L.L., S. Tang, C.P., J.-R.S.-M., M.C., H.C., Y.L., J.S.) - all in Massachusetts; Johns Hopkins University, Baltimore (C.A.H.); the University of Nantes, Nantes (P.M.), Hôpital Necker (L.F.), Hôpital Saint-Antoine (M.M.), and La Pitié-Salpêtrière Hospital (S.C.), Paris, University Hospital, Lille (T.F.), Centre Hospitalier Lyon Sud, Pierre-Benite (L.K.), and Centre Hospitalo-Universitaire Vandoeuvre-lès-Nancy, Nancy (A.P.) - all in France; the Mayo Clinic, Rochester, MN (D.D.); the University of Michigan, Ann Arbor (C.C.); the Mayo Clinic of Arizona, Phoenix (A.K.S.); Hackensack University Medical Center, Hackensack, NJ (J.R.); Washington University School of Medicine, St. Louis (R.V.); Lineberger Comprehensive Cancer Center at University of North Carolina-Chapel Hill, Chapel Hill (S. Tuchman); the University of Heidelberg, Heidelberg (M.S.R.), University Medical Center Hamburg-Eppendorf, Hamburg (K.C.W.), the University of Tübingen, Tübingen (K.C.W.), University Hospital Würzburg, Würzburg (M.S.), the University of Freiburg, Freiburg (M.E.), and Gemeinschaftspraxis Hämatologie-Onkologie, Dresden (T.I.) - all in Germany; the University of Leuven, Leuven (M. Delforge), Institut Jules Bordet, Université Libre de Bruxelles, Brussels (N.M.), University Hospital Ghent, Ghent (P.V.), and Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Yvoir (C.D.) - all in Belgium; Vanderbilt University Medical Center, Nashville (R.F.C.); Sylvester Cancer Center, University of Miami, Miami (J.E.H.); the University of Alabama at Birmingham, Birmingham (L.J.C.); Yale School of Medicine, New Haven, CT (T.L.P.); Baylor University Medical Center, Dallas (M.L.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (G.S.); and University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria (K.P.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1903455
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1903455DOI Listing
August 2019

Towards a better understanding of monoclonal gammopathy of renal significance.

Br J Haematol 2019 09 28;186(5):653-654. Epub 2019 May 28.

Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15989
Publisher Site
http://dx.doi.org/10.1111/bjh.15989DOI Listing
September 2019

A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.

Clin Adv Hematol Oncol 2019 May;17 Suppl 9(5):2-8

Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
May 2019

Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older.

J Geriatr Oncol 2019 05 22;10(3):486-489. Epub 2018 Nov 22.

Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18794068183034
Publisher Site
http://dx.doi.org/10.1016/j.jgo.2018.10.010DOI Listing
May 2019

The power of proteasome inhibition in multiple myeloma.

Expert Rev Proteomics 2018 12 14;15(12):1033-1052. Epub 2018 Nov 14.

b Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14789450.2018.1543595DOI Listing
December 2018

Ixazomib for the treatment of multiple myeloma.

Expert Opin Pharmacother 2018 Dec 13;19(17):1949-1968. Epub 2018 Nov 13.

g Hematology & Medical Oncology , Winship Cancer Institute, Emory University , Atlanta , GA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1528229DOI Listing
December 2018

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

N Engl J Med 2018 11;379(19):1811-1822

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Karol Marcinkowski University of Medical Sciences, Poznań (D.D.), and Silesian Medical University, Katowice (S.G.) - both in Poland; University Hospital, Nantes (P.M.), and Centre Hospitalier Universitaire de Poitiers-La Milétrie, Poitiers (X.L.) - both in France; National Hospital Organization Disaster Medical Center (N.T.) and the Japanese Red Cross Medical Center (K.S.), Tokyo, and Ibaraki Prefectural Central Hospital, Kasama (M.H.) - all in Japan; Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal (R.L.); Heidelberg University Hospital, Heidelberg, Germany (M.S.R.); Dana-Farber Cancer Institute, Boston (P.G.R.); Bristol-Myers Squibb, Princeton, NJ (M.P.M., Y.-M.J., S.G.S., M.R., B.R.); and Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain (J.S.-M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805762
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805762DOI Listing
November 2018

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.

Int J Hematol Oncol 2017 Nov 11;6(3):75-93. Epub 2017 Aug 11.

Department of Pediatric Hematology, Oncology & Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/ijh-2017-0015
Publisher Site
http://dx.doi.org/10.2217/ijh-2017-0015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171967PMC
November 2017

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.

Blood Adv 2018 10;2(19):2443-2451

Department of Medicine and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, Lebanon, NH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018016360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177641PMC
October 2018

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 01 3;25(1):137-144. Epub 2018 Aug 3.

Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.07.039DOI Listing
January 2019

How I treat the young patient with multiple myeloma.

Blood 2018 09 2;132(11):1114-1124. Epub 2018 Jul 2.

Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-05-693606DOI Listing
September 2018

Maintenance and continuous therapy for multiple myeloma.

Expert Rev Anticancer Ther 2018 08 3;18(8):751-764. Epub 2018 Jul 3.

d Department of Haematology , Mater Misericordiae University Hospital, University College Dublin , Dublin , Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1490181DOI Listing
August 2018

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Br J Haematol 2018 08 29;182(4):495-503. Epub 2018 May 29.

Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105456PMC
August 2018

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.

Br J Haematol 2018 05 10;181(4):433-446. Epub 2018 May 10.

Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15116DOI Listing
May 2018

Meaningful changes in end-of-life care among patients with myeloma.

Haematologica 2018 08 10;103(8):1380-1389. Epub 2018 May 10.

Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.187609DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068022PMC
August 2018

Current use of monoclonal antibodies in the treatment of multiple myeloma.

Br J Haematol 2018 05 25;181(4):447-459. Epub 2018 Apr 25.

Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15121DOI Listing
May 2018

Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Expert Rev Clin Pharmacol 2018 Feb 5;11(2):113-124. Epub 2018 Jan 5.

f Hematology Department , Hôpital Saint Antoine, AP-HP, Université Pierre & Marie Curie , Paris , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1421943DOI Listing
February 2018

Optimizing therapy for del(17p) multiple myeloma.

Oncotarget 2017 Dec 6;8(66):109859-109860. Epub 2017 Dec 6.

University Cancer Center of Toulouse Institut National de la Santé, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746348PMC
December 2017

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.

Future Oncol 2018 May 22;14(11):1035-1047. Epub 2017 Dec 22.

Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215-5450, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0616DOI Listing
May 2018

The proteasome and proteasome inhibitors in multiple myeloma.

Cancer Metastasis Rev 2017 12;36(4):561-584

Dana-Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-017-9707-8DOI Listing
December 2017

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.

Expert Opin Pharmacother 2017 Dec 1;18(18):1975-1985. Epub 2017 Dec 1.

d Blood and Marrow Transplant Program , Roswell Park Cancer Institute , Buffalo , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1409207DOI Listing
December 2017

CD38 antibodies in multiple myeloma: back to the future.

Blood 2018 01 8;131(1):13-29. Epub 2017 Nov 8.

Laboratory of Immunogenetics, Department of Medical Sciences and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-06-740944DOI Listing
January 2018

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.

Br J Haematol 2018 01 19;180(2):271-275. Epub 2017 Oct 19.

Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14970DOI Listing
January 2018

Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.

Expert Rev Gastroenterol Hepatol 2017 Oct 4;11(10):885-898. Epub 2017 Sep 4.

b Harvard Medical School, Jerome Lipper Multiple Myeloma Center , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2017.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2017.1370372DOI Listing
October 2017

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

J Clin Oncol 2017 Oct 25;35(29):3279-3289. Epub 2017 Jul 25.

Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6679DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652871PMC
October 2017

Drug Combinations with Transplantation for Myeloma.

N Engl J Med 2017 07;377(1):93-94

Centre Hospitalier Universitaire de Nantes-Hôtel Dieu, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1705671DOI Listing
July 2017

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

N Engl J Med 2017 04;376(14):1311-1320

From the Institut Universitaire du Cancer de Toulouse-Oncopole (M.A., M.R., C.P., S.R., H.A.-L.) and Service d'Epidémiologie, Centre Hospitalier et Universitaire de Toulouse (V.L.-C.), Toulouse, Hôpital Haut-Lévêque, Bordeaux Pessac (C.H.), Centre Hospitalier et Universitaire la Miletrie, Poitiers (X.L.), Centre Hospitalier Le Bocage, Dijon (D.C.), Centre Hospitalier et Universitaire de Rennes, Rennes (M.E.), Hôpital St.-Louis (B.A., J.P.F.), Centre Hospitalier Universitaire, Hôpital St.-Antoine (L.G.), Institut Curie (C.M.), and Haute Autorité de Santé (J.-L.H.), Paris, Institut d'Hématologie de Basse Normandie, Centre Hospitalier et Universitaire de Caen, Caen (M.M.), Centre Hospitalier et Universitaire Henri Mondor, Creteil (K.B.), Hôpital Claude Huriez, Lille (T.F.), and Hôtel Dieu, Nantes (P.M.) - all in France; Institut Jules Bordet, Brussels (N. Meuleman); and Dana-Farber Cancer Institute, Boston (M.E.M., A.A.Z., E.A.W., N. Munshi, K.C.A., P.G.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201242PMC
April 2017

Deacetylase inhibitors: an advance in myeloma therapy?

Expert Rev Hematol 2017 Mar 1;10(3):229-237. Epub 2017 Feb 1.

a Department of Hematologic Malignancies , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1280388DOI Listing
March 2017